Drug Trial Radar · NCT07580586
A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Mar 22, 2026
Primary completion
Sep 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- BioVersys SASIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, fixed sequence Phase I clinical study to evaluate the effect of multiple doses of BV100 on the PK of polymyxin B in healthy participants (HPs).
Conditions
- Healthy Adult Participants
Interventions
BV100 (300 mg)Drug
300 mg BV100 infused over 2 hours every 12 hours (q12h)
Polymyxin B (50 mg)Drug
500,000 IU (50 mg) polymyxin B infused over 2 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of repeated doses of intravenous (IV) BV100 on the pharmacokinetics (PK) of polymyxin BTime frame: 96 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of Vienna
Vienna, Austria · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.